

ASTRIA CONNECTION

May 2023

hae
day :-)

MANY FACES
ONE FAMILY

hae day :-) 2023

hae day :-) took place yesterday, May 16th!

Established in 2012 in the United States under Senate Resolution 286, it is now recognized worldwide as a day to spread awareness and education about HAE to doctors, researchers, and the general public. It also brings attention to the need for better therapies and improved quality of life. To learn more about how the community celebrated hae day :-) this year, click to visit the [hae day :- \) website](#) and [HAEA's photo wall](#).

hae day :-) at Astria

- Our team is in the middle of a month-long step-count challenge for HAEi's #Active4HAE campaign. On May 16th we did a companywide walk around Boston.
- We are proud to have new artwork reflective of the HAE experience—as shared by people living with HAE—hanging in our office.
- We participated in HAEA's photo wall campaign.
- Our office building shared information about HAE from HAEA on their app and on the screens located in elevators.



Community perspective:

Nathan, age 33, Hereditary Angioedema Type II

Has being on preventative therapy changed your experience of HAE?

“Before I was taking preventatives, I was afraid to travel out of the state. Since being on a preventative I feel like I can travel everywhere I want to go—I’m not trapped at home. I can do anything I want and that feels great.”

Astria STAR Council

Astria is excited to expand upon our collaborations with the HAE community by creating the STAR Council! The STAR Council will be composed of people living with HAE and their care partners, who will meet regularly with Astria's clinical, medical, and patient advocacy teams to provide feedback, preferences, and guidance on a number of different areas related to drug development. If you are living with HAE or are a care partner to someone with HAE, we invite you to apply for the STAR Council by completing this survey <https://bit.ly/3VKAUH6> by Wednesday, May 31.

Upcoming Events from HAEA/HAEi:

Click the date to learn more

- [May 18, 2023](#): HAEA Treatment Education Series Webinar: C1-INH Replacement Therapy to Treat the Root Cause of HAE Attacks
- [June 2, 2023](#): Become an HAEA Hero
- [July 20-23, 2023](#): 2023 US HAEA National Summit in Orlando, Florida
- [September 1-3, 2023](#): 2023 HAEi Regional Conference EMEA in Munich, Germany
- [September 12, 2023](#): 2023 US HAEA Virtual Capitol Hill Day
- [March 15-17, 2024](#): 2024 HAEi Regional Conference Americas in Panama City, Panama

ALPHA-STAR: New Trial Sites Opened!

The ALPHA-STAR trial is a proof-of-concept Phase 1b/2 trial evaluating single and multiple doses of STAR-0215 in people living with HAE types I and II. It is evaluating safety and tolerability, HAE attack rate, pharmacokinetics, pharmacodynamics, and quality of life in the enrolled participants. Learn more about the ALPHA-STAR trial and our trial sites by visiting www.astriatx.com/ALPHA-STAR.

About STAR-0215

We are charting a new path for people living with HAE—one that envisions an opportunity for a better quality of life with a safe and effective long-acting preventative therapy with dosing once every 3 months or longer.

STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein that is currently in preclinical development for the treatment of HAE. We expect to file an Investigational New Drug application for **STAR-0215** mid-year, and plan to initiate a Phase 1a clinical trial shortly thereafter, with initial results anticipated by year-end. We initiated the Phase 1b/2 trial in people living with HAE in 2023. Please see above for the study link.

Stay in touch!

Sign up to join our community and receive our newsletters in your inbox: <https://astriatx.com/for-patients/patient-newsletters/>

For advocacy questions: advocacy@astriatx.com

Follow us on social media: [@AstriaTx](#)

